Novel Approaches to Allergen Immunotherapy for Respiratory Allergies

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Nov 27

PMID 39598421

Authors

Mongkol Lao-Araya

Affiliations

Soon will be listed here.

Abstract

Allergen immunotherapy (AIT) remains the cornerstone for managing respiratory allergies, offering long-term symptom relief, disease modification, and prevention of disease progression. While novel approaches like intralymphatic and epicutaneous immunotherapy and the combination of allergens with adjuvants show promise, traditional methods remain effective and safe. Hypoallergenic T-cell peptide vaccines and recombinant allergens require further research to confirm their clinical benefits. Passive immunotherapy, while demonstrating effectiveness in specific cases, needs exploration of its long-term efficacy and broader applicability. Combining AIT with biologics may enhance safety and treatment outcomes. Despite emerging innovations, allergen-specific immunotherapy with natural allergen extracts remains the primary disease-modifying treatment, offering long-term symptom relief and prevention of disease progression. Continued research is essential to refine and optimize allergen immunotherapy strategies, providing patients with more effective and personalized treatment options.

References

Norman P, Lichtenstein L . Comparisons of alum-precipitated and unprecipitated aqueous ragweed pollen extracts in the treatment of hay fever. J Allergy Clin Immunol. 1978; 61(6):384-9. DOI: 10.1016/0091-6749(78)90118-5. View

Jutel M, Bruggenjurgen B, Richter H, Vogelberg C . Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy. 2020; 75(8):2050-2058. DOI: 10.1111/all.14240. View

Becker S, Zieglmayer P, Canto G, Fassio F, Yong P, Acikel C . A meta-analysis on allergen-specific immunotherapy using MCT (MicroCrystalline Tyrosine)-adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis. Clin Transl Allergy. 2021; 11(4):e12037. PMC: 8174800. DOI: 10.1002/clt2.12037. View

Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T . Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis. Int Arch Allergy Immunol. 2015; 166(3):177-88. DOI: 10.1159/000381059. View

Patel D, Couroux P, Hickey P, Salapatek A, Laidler P, Larche M . Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2012; 131(1):103-9.e1-7. DOI: 10.1016/j.jaci.2012.07.028. View

Kettner A, DellaCorte G, de Blay F, Jacobsen L, Jutel M, Worm M . Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. J Allergy Clin Immunol. 2018; 142(2):678-680.e7. DOI: 10.1016/j.jaci.2018.01.052. View

Mothes N, Heinzkill M, Drachenberg K, Sperr W, Krauth M, Majlesi Y . Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33(9):1198-208. DOI: 10.1046/j.1365-2222.2003.01699.x. View

Lin Y, Zimmermann J, Schulke S . Novel adjuvants in allergen-specific immunotherapy: where do we stand?. Front Immunol. 2024; 15:1348305. PMC: 10920236. DOI: 10.3389/fimmu.2024.1348305. View

Layhadi J, Lalioti A, Palmer E, van Zelm M, Wambre E, Shamji M . Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic. J Allergy Clin Immunol Pract. 2023; 12(1):59-66. DOI: 10.1016/j.jaip.2023.11.027. View

10.

Barber D, Diaz-Perales A, Escribese M, Kleine-Tebbe J, Matricardi P, Ollert M . Molecular allergology and its impact in specific allergy diagnosis and therapy. Allergy. 2021; 76(12):3642-3658. DOI: 10.1111/all.14969. View

11.

Olivieri B, Gunaydin F, Corren J, Senna G, Durham S . The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy. Ann Allergy Asthma Immunol. 2024; . DOI: 10.1016/j.anai.2024.06.016. View

12.

Bell A, Heath M, Hewings S, Skinner M . The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy. J Inorg Biochem. 2015; 152:147-53. DOI: 10.1016/j.jinorgbio.2015.08.007. View

13.

Marsh D, Lichtenstein L, CAMPBELL D . Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology. 1970; 18(5):705-22. PMC: 1455593. View

14.

Valenta R, Linhart B, Swoboda I, Niederberger V . Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011; 66(6):775-83. DOI: 10.1111/j.1398-9995.2011.02565.x. View

15.

Sharif H, Singh I, Kouser L, Mosges R, Bonny M, Karamani A . Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2019; 144(3):738-749. DOI: 10.1016/j.jaci.2019.02.023. View

16.

Sharif H, Acharya S, Dhondalay G, Varricchi G, Krasner-Macleod S, Laisuan W . Altered chromatin landscape in circulating T follicular helper and regulatory cells following grass pollen subcutaneous and sublingual immunotherapy. J Allergy Clin Immunol. 2020; 147(2):663-676. DOI: 10.1016/j.jaci.2020.10.035. View

17.

Durham S, Shamji M . Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2022; 23(5):317-328. PMC: 9575636. DOI: 10.1038/s41577-022-00786-1. View

18.

Gutermuth J, Grosber M, Pfaar O, Bergmann K, Ring J . 111 years of allergen-immunotherapy: A long and successful history of the only available disease-modifier in allergic diseases. Allergol Select. 2022; 6:248-258. PMC: 9707371. DOI: 10.5414/ALX02330E. View

19.

Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez J, Graf N . Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012; 129(5):1290-6. DOI: 10.1016/j.jaci.2012.02.026. View

20.

Bozek A, Cudak A, Canonica G . Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis. Allergy Asthma Proc. 2020; 41(4):271-277. DOI: 10.2500/aap.2020.41.200035. View